drug
ZINC
updated 5mo agoby HOSPIRA
community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying ZINC
- N/AZinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.
- phase3Comparative Efficacy of Different Dentin Occluding Toothpaste Technologies
- phase2Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
- phase4Evaluate the Efficacy of an Oral Health Behavioral Intervention in People With Diabetes
- phase3Investigation of Colgate Dual Zinc Toothpaste as Compared to Colgate Cavity Protection Toothpaste in Controlling Plaque and Gingivitis
- phase3Effect of Mouthwash in Reducing the Symptoms Associated With Flu and Cold Viruses
- phase3Efficacy of a Stannous Fluoride Toothpaste, Cetylpyridinium Chloride Mouthwash, and Battery Toothbrush Regimen in Reducing Established Dental Plaque and Gingivitis.
- N/AZinc Supplementation and Infections in Older Medical Patients
News(6)
- B. Braun Medical Inc. Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container Due to the Presence of Particulate MatterFOR IMMEDIATE RELEASE – September 3, 2026– Bethlehem, PA, B. Braun Medical Inc (B. Braun) is voluntarily recalling three (3) lots of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Con…fda_medwatch · 23d ago
- PTC takes a chance on Sangamo’s Fabry disease gene therapyWall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.biopharma_dive · 1mo ago
- Bankrupt Sangamo offloads assets to Lilly, PTC in $161M salePTC Therapeutics emerged as the winning bidder over Astellas for Sangamo Therapeutics’ Fabry disease gene therapy, while Eli Lilly is purchasing the biotech’s prion disease program and several plat…biospace · 1mo ago
- PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry marketPTC Therapeutics has struck a deal to buy Sangamo Therapeutics’ Fabry disease program for $111 million upfront, outbidding Astellas and TerSera Therapeutics for the near-approval gene therapy. Sang…fiercebiotech · 1mo ago
- How supplement use changed over decadesMedicare-funded weight loss, Utah's lower drunk driving limit, and more health news from Morning Roundsstat · 3mo ago
- FDA OKs first new sunscreen ingredient in more than 25 yearsFederal health regulators on Tuesday signed off on the first new sunscreen ingredient for the U.S. market in more than 25 years.stat · 3mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that